Generic
Brolucizumab
1 brands available in the market
At a glance
Brolucizumab is a human VEGF inhibitor used for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Description
Brolucizumab is a human VEGF inhibitor that binds to the three major isoforms of VEGF-A (VEGF 110, VEGF 121, and VEGF 165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Indications
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
Therapeutic class
Ophthalmic Preparations
Pharmacological class
VEGF Inhibitor
Pharmacology
Brolucizumab is a human VEGF inhibitor that binds to the three major isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Mechanism of action
Brolucizumab binds to VEGF-A, inhibiting vascular endothelial growth factor, which reduces abnormal blood vessel growth and fluid leakage, improving vision.
Dosage
Neovascular AMD: 6 mg (0.05 mL) monthly for first 3 doses, then 6 mg every 8-12 weeks.
Diabetic Macular Edema (DME): 6 mg every 6 weeks for first 5 doses, then 6 mg every 8-12 weeks.
Administration
This medicine is given as an intravitreal injection by an ophthalmologist.
Missed dose
Brolucizumab is an injection medicine given by healthcare professionals. You cannot miss a dose yourself.
Side effects
Common: Vision blurred, cataract, conjunctival hemorrhage, eye pain, vitreous floaters.
Precautions & warnings
Endophthalmitis and retinal detachment may occur; report symptoms immediately. Retinal vasculitis/occlusion has been reported. IOP increase may occur within 30 minutes of injection. Potential risk of ATE.
Contraindications
Ocular or periocular infections; active intraocular inflammation; hypersensitivity to any component.
Drug interactions
No adequate information on drug interactions is available.
Food interactions
Can be used with or without food.
Use in pregnancy
No adequate and well-controlled studies in pregnant women. Animal studies showed fetal loss and abnormality at 10-fold MRHD.
Pregnancy Category: N/A — always consult a doctor before taking during pregnancy.
Use in lactation
No information on presence in human milk. Breastfeeding is not recommended during treatment and for at least one month after the last dose.
Pediatric use
Safety and efficacy in pediatric patients have not been established.
Geriatric use
No specific dosage adjustment is necessary for elderly patients.
Renal / hepatic impairment
No special precautions are necessary for patients with kidney or liver problems.
Overdose effects
No adequate information on overdose is available.
Storage conditions
Refrigerate at 2-8°C (do not freeze). Store in outer carton to protect from light. May be kept at 20-25°C for up to 24 hours prior to use.
Chemical structure
Brolucizumab